Navigation Links
Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
Date:2/11/2009

ALISO VIEJO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that it will host a conference call on Tuesday, February 24, 2009 at 11:00 a.m. EST (8:00 a.m. PST) to discuss results for the 2008 fourth quarter and year.

The dial-in number to participate on this call is (877) 295-5743, confirmation code 83660030. International callers should dial (973) 200-3961, confirmation code 83660030. A replay will be available approximately two hours following the conclusion of the conference call to Tuesday, March 3, 2009, and can be accessed by dialing (800) 642-1687 or (706) 645-9291, confirmation code 83660030.

The company also will webcast the call live over the Internet, which will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

    Contact:
    Laurie W. Little, Valeant Pharmaceuticals
    949-461-6002

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Biotest Pharmaceuticals Corporation Acquires Santa Fe, New Mexico Plasmapheresis Center
3. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
4. Par Pharmaceutical Announces Outcome of the Litigation With Pentech Pharmaceuticals
5. Mpex Pharmaceuticals Announces Series D Financing of Up to $40 Million
6. Prism Pharmaceuticals Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
7. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
8. Pharmaceuticals sold in Sweden cause serious environmental harm in India
9. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
10. Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results
11. Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from ... May 30th and 31st at The Four Seasons Hotel Boston. , The ... life sciences, offering exclusive access to key decision makers who influence deal making ...
(Date:5/26/2017)... ... 2017 , ... Boar’s Head Brand®, one of the nation’s ... entertaining that are sure to satisfy your guests’ flavor cravings, while adding delicious ... featured in these refreshingly balanced recipes are packed with flavor, creating the perfect ...
(Date:5/26/2017)... ... 2017 , ... Silver Birch of Hammond, a new assisted lifestyle community, has ... acres of land at 5620 Sohl Avenue in Hammond, serves older adults who need ... studio and one-bedroom apartments. Each of the private apartments at Silver Birch features a ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... recipient of proceeds from its 14th Annual Clays for Kids fundraiser, to be ... 30, Bennett, Colorado. , As part of BluSky’s partnership with The Adoption ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, ... most appropriate instruments for research and understanding the basic principles that were designed ... focus on innovations in stereo microscopy for brightfield and fluorescence typically used in ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... May 9, 2017  Demonstrating its commitment to ... directors for the Pharmaceutical Research and Manufacturers of ... Biopharmaceutical companies will now have to meet new ... be eligible to join PhRMA. "By ... is sending a clear message that being a ...
(Date:5/8/2017)... Mich. , May 8, 2017  Diplomat Pharmacy, ... WRB Communications, Inc. ("WRB"), a health care service ... . WRB specializes in relationship management programs ... WRB will join ... Diplomat,s commercialization support services for manufacturers, biotech firms, and ...
(Date:5/4/2017)... , May 4, 2017  Fortuna Fix Inc. (" Fortuna ... be the first to eliminate the need for embryonic and ... to treat neurodegenerative diseases. Fortuna announced ... Professor Michael Fehlings , MD, PhD; Father Kevin ... MD, MPH; and Professor James Giordano , PhD. ...
Breaking Medicine Technology: